Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities

Abstract

Although emerging therapies for mCRPC mean that the future is bright, guidelines are needed to ensure optimum use and sequencing of treatments. Additional costs and anticipated workload associated with new agents will require careful consideration.